The takeover – which was completed on July 26 – includes Micro-Macinazione’s active pharmaceutical ingredient (API) processing site and recently expanded warehouse in Monteggio, Switzerland.
A Lonza spokesman told us: “Micro-Macinazione has 120 employees and is based in Monteggio, Switzerland. We will take over the entire site.
He added that: “Micro-Macinazione provides micronization technology and expertise that complements our existing US capabilities and provides significant additional capacity to support our growth.”
Lonza said demand for micronization and sub-micronization is increasing as customers seek to improve the bioavailability and efficacy of their products.
The Swiss life science supplier’s main drug ingredient micronization capabilities are located at a facility in Quakertown, Pennsylvania that is owned by recent acquisition Capsugel.
News of the acquisition comes a little over a year after Capsugel said it planned to increase micronization capacity at the Quakertown site.
Small molecules, major driver
In July Lonza predicted it will generate annual revenue of CHF7.5bn ($7.9bn) by 2022 citing the expansion of its offering provided by Capsugel as an important driver.
The firm reported that its harma&biotech segment generated revenue of CHF1.06bn in the first half of 2017, up 27% on the equivalent period last year.
It cited “positive performance within chemical manufacturing” adding that “Small molecules made a significant improvement compared to the prior year due to better commercial offerings to existing and new customers.”